Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ECC 2015 | Role of BRAF mutation in the treatment for melanoma

At the European Cancer Congress (ECC) 2015, Dirk Schadendorf, MD, PhD, from Universitätsklinikum Essen, Essen, Germany, discusses advances in the biological understanding of BRAF-mutant melanoma, which involves the constitutive activation of the MAPK pathway and have led to the development of new targeted therapies for patients with metastatic disease.